Market Research Logo

Left Ventricular Dysfunction - Pipeline Review, H2 2015

Left Ventricular Dysfunction - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Left Ventricular Dysfunction - Pipeline Review, H2 2015’, provides an overview of the Left Ventricular Dysfunction’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Left Ventricular Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Left Ventricular Dysfunction and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Left Ventricular Dysfunction
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Left Ventricular Dysfunction and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Left Ventricular Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Left Ventricular Dysfunction pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Left Ventricular Dysfunction
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Left Ventricular Dysfunction pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Left Ventricular Dysfunction Overview
Therapeutics Development
Pipeline Products for Left Ventricular Dysfunction - Overview
Pipeline Products for Left Ventricular Dysfunction - Comparative Analysis
Left Ventricular Dysfunction - Therapeutics under Development by Companies
Left Ventricular Dysfunction - Therapeutics under Investigation by Universities/Institutes
Left Ventricular Dysfunction - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Left Ventricular Dysfunction - Products under Development by Companies
Left Ventricular Dysfunction - Products under Investigation by Universities/Institutes
Left Ventricular Dysfunction - Companies Involved in Therapeutics Development
Acorda Therapeutics, Inc.
Amgen Inc.
Bayer AG
Innopharmax Inc.
RedHill Biopharma Ltd.
TiGenix NV
Left Ventricular Dysfunction - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
BAY-1142524 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CAP-1001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CAP-1002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
carvedilol CR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
carvedilol CR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cimaglermin alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CTX-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
omecamtiv mecarbil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Target O2 Radical for Left Ventricular Dysfunction and Diabetic Complications - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Left Ventricular Dysfunction - Recent Pipeline Updates
Left Ventricular Dysfunction - Dormant Projects
Left Ventricular Dysfunction - Discontinued Products
Left Ventricular Dysfunction - Product Development Milestones
Featured News & Press Releases
Aug 27, 2013: Amgen to Highlight New Data at Upcoming ESC Congress 2013
Jun 18, 2013: Cytokinetics Announces Presentation Of Results From Phase IIb Clinical Trial Of Omecamtiv Mecarbil At ESC Congress 2013
Feb 19, 2013: RedHill Biopharma Announces Notice Of Allowance From US Patent And Trademark Office For Cardio Drug RHB-101
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Left Ventricular Dysfunction, H2 2015
Number of Products under Development for Left Ventricular Dysfunction - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Left Ventricular Dysfunction - Pipeline by Acorda Therapeutics, Inc., H2 2015
Left Ventricular Dysfunction - Pipeline by Amgen Inc., H2 2015
Left Ventricular Dysfunction - Pipeline by Bayer AG, H2 2015
Left Ventricular Dysfunction - Pipeline by Innopharmax Inc., H2 2015
Left Ventricular Dysfunction - Pipeline by RedHill Biopharma Ltd., H2 2015
Left Ventricular Dysfunction - Pipeline by TiGenix NV, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Left Ventricular Dysfunction Therapeutics - Recent Pipeline Updates, H2 2015
Left Ventricular Dysfunction - Dormant Projects, H2 2015
Left Ventricular Dysfunction - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Left Ventricular Dysfunction, H2 2015
Number of Products under Development for Left Ventricular Dysfunction - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report